Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 14/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10317278 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1GCK | |
| SCHEMBL10317618 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1GCK | |
| SCHEMBL1271316 | 0.89 | GCK (0.52) | GCK | |
| SCHEMBL10317557 | 0.89 | GCK (0.52) | GCK | |
| SCHEMBL10318592 | 0.89 | GCK (0.52) | GCK | |
| SCHEMBL10318558 | 0.86 | GCK (0.47) | GCK | |
| SCHEMBL1272031 | 0.86 | NPC1 (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1GCK | |
| SCHEMBL10318342 | 0.86 | NPC1 (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1GCK | |
| SCHEMBL10319198 | 0.86 | NPC1 (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1GCK | |
| SCHEMBL10318557 | 0.86 | GCK (0.47) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835469-B2 | Substituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2014-09-16 | — | — | US | claimed |
| EP-2459554-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LTD (IN) | 2013-09-18 | — | — | EP | claimed |
| US-20120184544-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-07-19 | — | — | US | claimed |
| US-8835469-B2 | Substituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2014-09-16 | — | — | US | disclosed |
| EP-2459554-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LTD (IN) | 2013-09-18 | — | — | EP | disclosed |
| US-20120184544-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184544-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | GCKR, GCK, GK | SMN1; SMN2 2632/4885NPC1 1459/4885RAB9A 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.